This treat-to-target approach was used to help and enable patients to achieve tight blood glucose control and allow the different insulin regimens to be compared in terms of ease of use, acceptability, clinical outcomes (e.g. weight effects, risk of hypoglycemia and impact on microalbuminuria), and patient adherence. The gene discussed is INS; the disease is Hypoglycemia.